Qiao Zhou

Expertise

  • PBMC cell extraction
  • Cell Culture
  • Immunostaining
  • Flow Cytometry
  • Animal dissection
  • 2008–2013, Staff Research Associate, UCLA, Los Angeles, CA
  • 2008, UCLA, Los Angeles, CA, B.S. in Biochemistry
  • La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva T, Tsai W, Drake J, Carroll M, Wussow F, Chiuppesi F, Dadwal S, Aldoss I, Nakamura R, Zaia JA, Diamond DJ.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T-cells in healthy adults independent of CMV serostatus, Blood, Submitted 07/22/2016
  • Nakamura R, La Rosa C (co-1st author), Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O’Donnell M, Cai J, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ. 2015. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016 Feb;3(2):e87-98. Epub 2015 Dec 24. PMID: 26853648
  • Diamond DJ, La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva T, Drake J, Carroll M, Dadwal S, Aldoss I, Nakamura R, Zaia JA.2015. Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia [abstract]. In: American Society of Hematology 57th Annual Meeting & Exposition; 2015 Dec 5-8; Orlando, FL. ASH; Abstract nr 3108.
Back To Top